semaglutide deaths 2024 flow trial renal outcomes Results from this major show that reduced the risk of New weight-loss drugs surge in

Lasting recovery requires rebuilding resilience at the metabolic, structural, immune, and neurologic levels

Down to 168 now at week 26

From its pharmacodynamics and suggested dosage, to regulatory safety findings and required lab supplies, this expert rundown has you covered

R.SchultzW

Indications: FDA approved: Type II diabetes - monotherapy or combination therapy Can be combined as adjunct therapy with other hypoglycemics including metformin, thiazolidinediones, or insulin regimens (Dungan & DeSantis 2015) Because it does not work when your blood sugar is low, it is unlikely to produce dangerous levels of hypoglycemia has been observed in clinical trials (in contrast to GLP-1 incretin mimetics, such as exenatide, which produce moderate weight loss)

injection in the vein (IV) or intramuscular (IM) every 2 weeks